Part two: Industry examining FDA guidance on nitrosamines...
This summer, a wave of regulatory activity on nitrosamines has taken place, with agencies from around the world recently publishing new or revised guidances on nitrosamines.
This year has seen a flurry of activity by the U.S. Food and Drug Administration surrounding ophthalmic products.
Nitrosamines are naturally occurring chemical compounds that people are regularly exposed to at low levels.
Substandard medicines are a huge public health threat. Proactively evaluating drug products using a relative risk assessment is important to reduce the prevalence of substandard antibiotics.
The World Health Organization (WHO) recently issued a Medical Product Alert after four substandard products were identified in The Gambia, which may be linked to t
Revised on: January 17, 2023
Persistent and long-lasting shortages of childhood cancer treatments undermine the advancements in science that have helped to increase childhood cancer survival rates to 85 percent.